Home › Blog › Weight Loss › Best Weight Loss Injections UK 2026

The Best Weight Loss Injections in the UK 2026: A Superintendent Pharmacist’s Complete Guide

Overview: Key Findings for 2026

Weight loss injections have fundamentally changed what is clinically possible in obesity treatment. As a superintendent pharmacist with 25 years in clinical practice, I have watched this category evolve from modest early GLP-1 options to the extraordinary efficacy we see with tirzepatide today. The clinical evidence is genuinely impressive — but the explosion in online providers means patients now face a more complex decision than simply choosing a medication.

This guide covers everything: the clinical evidence, the safety data, the side effect profiles, the real costs, the eligibility criteria, and — critically — how to identify a provider you can actually trust. I have written it to be the most thorough, most honest, and most clinically grounded guide available in the UK.

Based on current clinical trial data, the most effective weight loss injection available in the UK in 2026 is tirzepatide (Mounjaro), with average weight loss of 22.5% of starting body weight at the 15mg dose over 72 weeks.¹ The newly MHRA-approved higher dose of semaglutide (Wegovy 7.2mg) produced average weight loss of 20.7% in the STEP UP trial.²

Both medications are available at Slinic’s online weight loss clinic at fixed prices from £139 per month — no subscription, no hidden fees, and full clinical oversight from a GPhC-registered, NHS-contracted pharmacy team.

How Weight Loss Injections Work

To make a genuinely informed choice, it helps to understand the mechanism. Weight loss injections belong to a class of medicines called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It signals fullness to the brain, slows gastric emptying, and stimulates insulin release to regulate blood sugar. When you inject a GLP-1 receptor agonist, you amplify and extend this natural signal — producing sustained appetite suppression and significantly reduced calorie intake without the constant hunger battle of conventional dieting.

GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that enhances insulin secretion and has additional metabolic effects on adipose tissue. Mounjaro activates both GIP and GLP-1 receptors simultaneously — the dual-action mechanism that explains why its trial results stand apart from anything seen before in obesity pharmacotherapy. Beyond weight loss, this mechanism is also why GLP-1 agonists are showing promising results for systemic inflammation and joint health — a topic we explore in depth in our clinical guide to GLP-1 agonists and joint pain.

Weight Loss Injections UK 2026: At-a-Glance Comparison

1. Mounjaro (Tirzepatide): The Most Effective Weight Loss Injection in 2026

Mounjaro is the most effective prescription weight loss injection currently available in the UK. Licensed by the MHRA in 2023 and manufactured by Eli Lilly, it works on two hormone pathways — GLP-1 and GIP — where all previous weight loss injections worked on only one. This dual-receptor mechanism is the reason its clinical trial results stand apart from anything seen before in obesity pharmacotherapy. For a deeper explanation of the mechanism, read our guide on how Mounjaro works for weight loss.

It is delivered as a once-weekly subcutaneous injection using a pre-filled KwikPen. Treatment begins at 2.5mg and is increased every four weeks in a structured escalation protocol, allowing the body to adapt at each stage and minimising the gastrointestinal side effects that some patients experience at higher doses.

Clinical Evidence for Mounjaro

The SURMOUNT-1 trial is the landmark Phase 3 study. In 2,539 adults with obesity without type 2 diabetes, the 15mg dose produced:¹

• Average weight loss of 22.5% of starting body weight at 72 weeks
• 91% of participants achieved at least 5% weight loss
• 57% achieved at least 20% weight loss
• 36% achieved at least 25% — results previously associated only with bariatric surgery

The SURMOUNT-2 trial, conducted in adults with obesity and type 2 diabetes, showed average weight loss of 15.7% at the 15mg dose — significant given that metabolic conditions typically attenuate GLP-1 response.³

A 2025 head-to-head trial published in the New England Journal of Medicine directly compared tirzepatide with semaglutide 2.4mg and found that tirzepatide produced statistically significantly greater weight loss across all doses tested.⁴ Long-term data from the SURMOUNT-4 trial demonstrated that weight loss is maintained at 88 weeks with continued treatment, and that discontinuing without having established lifestyle habits leads to significant weight regain within 12 months — underscoring the importance of ongoing clinical support.⁵

Mounjaro Dosing Schedule

p>For a full breakdown of each dose stage and what to expect at each phase, see our complete Mounjaro dosing schedule guide and our guide to Mounjaro week 1 and month 1 results.

Who is Eligible for Mounjaro?

For private prescription through Slinic, eligibility typically requires a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition. See our full Mounjaro eligibility UK 2026 guide for complete clinical criteria and how to qualify.

Who Cannot Take Mounjaro?

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It must be stopped at least two months before attempting to conceive. Additional clinical assessment is required for patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy. This is precisely why a thorough clinical assessment — not a two-minute online questionnaire — is essential before prescribing.

2. Wegovy (Semaglutide): Proven Efficacy and the New 7.2mg Option

Wegovy was the first obesity-specific GLP-1 receptor agonist to receive NICE approval for NHS use in the UK and remains one of the most widely prescribed weight loss medications in the world. It is manufactured by Novo Nordisk and delivered as a once-weekly subcutaneous injection. In January 2026, the MHRA approved a higher 7.2mg dose — a significant development that brings Wegovy’s efficacy much closer to Mounjaro’s trial results. For a detailed side-by-side comparison, see our Mounjaro vs Wegovy guide.

Clinical Evidence for Wegovy

• STEP 1 trial: Average weight loss of 14.9% at the 2.4mg maintenance dose over 68 weeks. 86.4% achieved at least 5% weight loss.⁷
• STEP UP trial (7.2mg dose): Average weight loss of 20.7% over 72 weeks. Approximately 1 in 3 participants lost 25% or more of their starting body weight.²
• SELECT trial: Wegovy is currently the only weight loss injection in the UK with a cardiovascular benefit on its official label. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in adults with existing heart disease and obesity without diabetes.⁸

Three Reasons People Are Choosing Wegovy in 2026

Following Mounjaro’s September 2025 price increase, Wegovy has become increasingly attractive for three practical reasons. First, cost — Wegovy 2.4mg is typically more affordable per month than Mounjaro at its maintenance doses, and the 7.2mg dose delivers near-comparable efficacy. Second, cardiovascular evidence — Wegovy is currently the only weight loss injection with heart-health benefits on its official licence label, relevant for patients with existing cardiovascular disease. Third, safety track record — Wegovy has the longest real-world safety data of the newer weekly injections, with millions of doses administered worldwide since 2021.

Wegovy 7.2mg: What You Need to Know

The 7.2mg dose is not a starting dose. It is intended for patients who have already reached and tolerated the 2.4mg maintenance dose but have plateaued or require additional weight loss. Currently administered as three consecutive 2.4mg injections on the same day. A dedicated single-injection 7.2mg pen is expected later in 2026. See our complete Wegovy 7.2mg guide for the full clinical criteria and what to expect.

Wegovy Dosing Schedule

3. Saxenda (Liraglutide): Still Available, Rarely the Right Choice in 2026

Saxenda (liraglutide 3mg) is a daily injection that was widely used before the weekly options became available. It remains NICE-approved under TA664 for tier 3 NHS weight management services, but is now rarely the appropriate first choice in 2026 given the substantially better outcomes and more convenient dosing schedule of Mounjaro and Wegovy.

The SCALE clinical trials demonstrated average weight loss of 5–7% over 56 weeks — significant compared with no treatment, but considerably lower than the newer weekly medications.⁹ Discontinuation rates are also higher with Saxenda, partly due to the daily injection burden. Saxenda’s original patent expired in 2025 and the branded Novo Nordisk version has experienced prolonged supply difficulties. Generic versions including Biolide (Biocon) and Nevolat are now available. Slinic does not routinely prescribe liraglutide given the availability of superior options, but our clinical team can advise if it is specifically relevant to your circumstances.

When Saxenda May Still Be Appropriate

Saxenda may be considered if you have not previously tolerated weekly GLP-1 medications, prefer daily dosing (which allows stopping more quickly if side effects occur), or if Wegovy and Mounjaro are clinically contraindicated. On the NHS, liraglutide is still listed for specialist tier 3 weight management services under NICE TA664, but is now rarely prescribed as a first choice.

Side Effects: A Detailed Clinical Comparison

All three medications share a similar gastrointestinal side effect profile because they all activate GLP-1 receptors. The severity and duration of side effects depends significantly on how carefully the dose escalation is managed — which is one of the reasons ongoing clinical oversight is not optional, it is essential. For a full patient-facing breakdown see our Mounjaro side effects guide.

Serious but Rare Side Effects

• Pancreatitis — fewer than 0.2% of users. Severe, persistent abdominal pain radiating to the back requires immediate medical attention and discontinuation of medication.
• Gallbladder problems — gallstones in approximately 1–2% of users, more common with rapid weight loss. Symptoms include upper right abdominal pain, nausea, and fever.
• Diabetic retinopathy changes — patients with existing diabetic retinopathy require close monitoring, as rapid improvement in blood sugar control can temporarily worsen retinopathy. This requires discussion with your clinician before starting.
• Allergic reactions — rare but require immediate emergency attention if anaphylaxis symptoms occur including rash, difficulty breathing, or facial swelling.

NHS vs Private Access in 2026

NHS Access in 2026: The Reality

Mounjaro on the NHS: NICE TA1026 approved tirzepatide for NHS prescribing in 2025. A phased GP rollout began in June 2025 but initial eligibility is highly restricted — typically BMI 40 or above with at least four weight-related health conditions. This threshold will widen gradually over a 12-year rollout, but for most patients with a BMI between 30 and 40, NHS Mounjaro is not currently accessible.

Wegovy on the NHS: Available through specialist tier 3 weight management services under NICE TA875, requiring a BMI of 35 or above with weight-related health conditions. Waiting times in most English ICBs currently range from 12 to 24 months. The newly approved 7.2mg dose has not yet received NICE approval for NHS use.

If you believe you may meet NHS eligibility criteria, I would always encourage you to explore that route with your GP first. But if your BMI falls below the NHS threshold, or you are not prepared to wait 12 months or longer, a GPhC-registered private provider with proper clinical oversight is the right and safe route.

Cost Analysis: What You Are Really Paying in 2026

For a complete dose-by-dose breakdown, see our dedicated Mounjaro cost UK 2026 guide and our guide to safe, affordable weight loss injections in the UK.

Comparing costs across UK providers requires more care than it might appear. Many providers advertise a low starting price but then add consultation fees, prescription charges, needles, sharps bins, and delivery on top. The only figure that matters is the true all-inclusive total — and whether the provider is actually NHS-contracted and GPhC-regulated. For an independent provider comparison see our Top UK Mounjaro Providers guide.

Prices verified at time of publication. Always confirm directly with each provider. For Slinic’s current pricing visit slinic.co.uk.

Eligibility Criteria

See our full Mounjaro eligibility UK 2026 guide for complete criteria. For private prescription at Slinic you are likely eligible if you have:

• A BMI of 30 or above, or
• A BMI of 27 or above with at least one of: type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, cardiovascular disease, or non-alcoholic fatty liver disease
• Age 18 or over
• Not pregnant or breastfeeding
• No absolute contraindications — assessed fully at clinical review

How to Choose a Weight Loss Injection Provider Safely

The growth of the UK weight loss injection market has unfortunately attracted providers who do not meet the necessary clinical standards. The GPhC and the Royal Pharmaceutical Society have both issued public warnings about online providers approving prescriptions without proper clinical assessment. Before committing to any provider, check the following:

1. Verify GPhC registration — search pharmacyregulation.org. Slinic’s number is 1033729.
2. Check LegitScript certification — the international standard for verified online pharmacies. Verify Slinic’s LegitScript certification here.
3. Confirm independent weight verification — required under February 2025 GPhC guidance.
4. Ask who reviews your clinical assessment — must be a registered UK prescriber, not an automated algorithm.
5. Get the complete total price upfront — including consultation, needles, sharps, and delivery.
6. Check for subscription lock-in — understand the cancellation policy before you sign up.
7. Confirm ongoing clinical support — your provider should offer regular clinical check-ins, not just prescription renewals.

Weight Loss Medications in Development: What Is Coming

The weight loss pharmacotherapy pipeline is the most active it has ever been. Our dedicated guide to retatrutide UK progress and expected availability 2026 covers the next generation in full. Here is a clinical summary:

Retatrutide (Eli Lilly) — Triple Agonist

Retatrutide activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. That is one more than Mounjaro, which activates two. In the TRIUMPH-1 Phase 3 trial — the first large-scale obesity trial for this drug — participants achieved an average weight loss of 28.3% at the 12mg dose over 80 weeks.¹⁰ Eli Lilly reported these topline results in 2026 ahead of full peer-reviewed publication. Nearly half of participants at the highest dose lost 30% or more of their body weight — a level previously associated only with bariatric surgery. A notable safety signal is dysaesthesia, reported in approximately 1 in 5 participants at the 12mg dose, though most cases resolved whilst continuing treatment. If results hold across further TRIUMPH trials, regulatory submission could follow in late 2026 or 2027, with UK availability most likely in 2027–2028.

Oral Semaglutide (Novo Nordisk)

An oral form of semaglutide for weight loss launched in the US in January 2026. The OASIS-4 trial showed average weight loss of approximately 13.6% over 64 weeks. The MHRA is reviewing it, with a decision expected towards end of 2026. If approved, it would offer an alternative for patients who prefer a tablet to an injection.

CagriSema (Novo Nordisk)

CagriSema combines semaglutide with cagrilintide, an amylin analogue, targeting two different hormonal pathways. The REDEFINE 1 trial showed average weight loss of approximately 22.7% in patients who completed treatment. Novo Nordisk submitted CagriSema to the FDA in December 2025, with UK availability expected in 2027 at the earliest.

Orforglipron / Foundayo (Eli Lilly)

FDA-approved in April 2026, orforglipron is a daily oral GLP-1 agonist with average weight loss of approximately 12% in Phase 3 trials. Unlike oral semaglutide, it can be taken at any time of day without food or water timing requirements. MHRA submission is expected but not yet confirmed.

Frequently Asked Questions

Clinical References

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387(3):205-216. (SURMOUNT-1)
2. Wharton S, et al. Once-weekly semaglutide 7.2mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology. 2025;13(11):949-963.
3. Garvey WT, et al. Tirzepatide once weekly for obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet. 2023;402(10402):613-626.
4. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. NEJM. 2025;393(1):26-36.
5. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
6. MHRA Drug Safety Update: Tirzepatide (Mounjaro). January 2025.
7. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021;384(11):989-1002.
8. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. 2023;389(24):2221-2232.
9. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0mg of Liraglutide in Weight Management (SCALE). NEJM. 2015;373(1):11-22.
10. Eli Lilly. TRIUMPH-1 topline results. 2026. (Topline only — not yet peer-reviewed.)
11. NICE TA1026 — Tirzepatide for managing overweight and obesity.
12. NICE TA875 — Semaglutide for managing overweight and obesity.
13. GPhC. Guidance for registered pharmacies providing services at a distance. Updated February 2025. pharmacyregulation.org

Related Guides & Treatment Pages